Newer options in the management of acromegaly

Internal Medicine Journal

Volumn 36, Issue 7, 2006, Pages 437-444

  Burt, M G ^a   Ho, K K Y ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Acromegaly; Dopamine agonist; Pegvisomant; Somatostatin analogue; Stereotactic radiotherapy

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; LANREOTIDE AUTOGEL; LANREOTIDE SR; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACROMEGALY; ADD ON THERAPY; BLOATING; CANCER CONTROL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIABETES INSIPIDUS; DIARRHEA; DISEASE CONTROL; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; EARLY INTERVENTION; ENDOCRINE SURGERY; GALLSTONE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOTHYROIDISM; LIQUORRHEA; LIVER DYSFUNCTION; META ANALYSIS; MICROADENOMA; MORTALITY; NAUSEA; OPTIC CHIASM; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; VISUAL IMPAIRMENT;

ACROMEGALY; ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; DOPAMINE AGONISTS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; RADIOTHERAPY; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 33745022151     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01097.x     Document Type: Review

References (47)

1. Rajasoorya C Holdaway IM Wrightson P Scott DJ Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994 41 : 95 102.
2. Orme SM McNally RI Cartwright RA Belchez PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998 83 : 2730 4.
3. Bates AS Vant Hoff W Jones JM Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993 86 : 293 9.
4. Abosch A Tyrell JB Lamborn KR Hannegan LT Applebury CB Wilson CB. Transphenoidal microsurgery for growth-hormone secreting pituitary adenomas: initial outcome and long term results. J Clin Endocrinol Metab 1998 83 : 3411 18.
5. Swearingen B Barker FG II. Katznelson L Biller BMK Grinspoon S Klibanski A et al. Long-term mortality after transphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998 83 : 3419 26.
6. Holdaway IM Rajasoorya RC Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004 89 : 667 74.
7. Biermasz NR Dekker FW Pereira AM van Thiel SW Schutte PJ van Dulken H et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004 89 : 2789 96.
8. Grunstein RR Ho KY Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991 115 : 527 32.
9. Ho KKY Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol 1994 41 : 75 83.
10. Giustina A Barkan A Casanueva FF Cavagnini F Frohman L Ho K et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000 85 : 526 9.
11. Freda PU. How effective are current therapies for acromegaly? Growth Horm IGF Res 2003 13 : S144 51.
12. Lissett CA Peacey SR Laing I Tetlow L Davis JRE Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol 1998 49 : 653 7.
13. Sheaves R Jenkins P Blackburn P Huneidi AH Afshar F Medbak S et al. Outcome of transphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996 54 : 407 13.
14. Wass JAH. Radiotherapy in acromegaly: a protagonists viewpoint. Clin Endocrinol 2003 58 : 128 31.
15. Barkan AL. Radiotherapy in acromegaly: the argument against. Clin Endocrinol 2003 58 : 132 5.
16. Powell JS Wardlow SL Post KD Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000 85 : 2068 71.
17. Biermasz NR van Dulken H Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000 85 : 2476 82.
18. Simmons NE Laws ER. Glioma occurrence after sellar irradiation: case report and review. Neurosurgery 1998 42 : 172 8.
19. Ayuk J Clayton RN Holder G Sheppard MC Stewart PM Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-1 concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004 89 : 1613 17.
20. Tomlinson JW Holden N Hills RK Wheatley K Clayton RN Bates AS et al. Association between premature mortality and hypopituitarism. Lancet 2001 357 : 425 31.
21. Lamberts SWJ Van Der Lely AJ De Herder WW Hofland LJ. Octreotide. N Engl J Med 1996 334 : 246 54.
22. Saveanu A Gunz G Dufour H Caron P Fina F Ouafik L et al. BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001 86 : 140 5.
23. Ho KY Weissberger AJ Marbach P Lazarus L. Therapeutic efficacy of the somatostatin analog 201-995 (octreotide) in acromegaly: effects of dose and frequency and long-term safety. Ann Intern Med 1990 112 : 173 81.
24. Flogstad AK Halse J Bakke S. Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab 1997 82 : 23 8.
25. Lancranjan I Atkinson AB, Sandostatin LAR Group. Results of a European Multicentre study with Sandostatin LAR in acromegalic patients. Pituitary 1999 1 : 105 19.
26. Cozzi R Attanasio R Montini M Pagani G Lasio G Lodrini S et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results. J Clin Endocrinol Metab 2003 88 : 3090 8.
27. Caron P Morange-Ramos I Cogne M Jaquet P. Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997 82 : 18 22.
28. Baldelli R Colao A Razzore P Jaffrain-Rea M-L Marzullo P Ciccarelli E et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000 85 : 4099 103.
29. Attanasio R Baldelli R Pivonello R Grottoli S Bocca L Gasco V et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 2003 88 : 5258 65.
30. Freda PU. Clinical review 150. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002 87 : 3013 18.
31. Caron PH Beckers A Cullen DR Goth MI Gutt B Laurberg P et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002 87 : 99 104.
32. Lim MJ Barkan AL Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992 117 : 719 26.
33. Grunstein RR Ho KKY Sullivan CE. Effect of somatostatin analog (octreotide) on sleep apnea in acromegaly. Ann Intern Med 1994 121 : 478 83.
34. Melmed S Dowling RH Frohman L Ho KKY Lamberts S Lamont JT et al. Consensus statement: benefits versus risks of medical therapy for acromegaly. Acromegaly therapy consensus development panel. Am J Med 1994 97 : 468 73.
35. Jaffe CA Barkan AL. Treatment of acromegaly with dopamine agonists. Clin Endocrinol Metab 1992 21 : 713 35.
36. Abs R Verhelst J Maiter D Van Acker K Nobels F Coolens JL et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998 83 : 374 8.
37. Colao A Ferone D Marzullo P Di Sarno A Cerbone G Sarnacchiaro F et al. Effect of different dopaminergenic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997 82 : 518 823.
38. Kopchick JJ. Discovery and mechanism of action of pegvisomant. Eur J Endocrinol 2003 148 : S21 5.
39. Trainer PJ Drake WM Katznelson L Freda P Herman-Bornet V van der Lely AJ et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000 342 : 1171 7.
40. van der Lely AJ Hutson RK Triner PJ Besser GM Barkan AL Katznelson L et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 : 1754 9.
41. Drake WM Rowles SV Roberts ME Fode FK Besser GM Monson JP et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003 149 : 521 7.
42. Ho KKY. Place of pegvisomant in acromegaly. Lancet 2001 358 : 1743 4.
43. Newman CB Melmed S George A Torigian D Duhaney M Snyder P et al. Octreotide as a primary therapy for acromegaly. J Clin Endocrinol Metab 1998 83 : 3034 40.
44. Petrossians P Borges-Martins L Espinoza C Daly A Betea D Valdes-Socin H et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005 152 : 61 6.
45. Hofland LJ van der Hoek J van Koetsveld PM De Herder WW Waaijers M Sprij-Mooij D et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth-hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004 89 : 1577 85.
46. van der Hoek J De Herder WW Feelders RA Van der Lely AJ Uitterlinden P Boerlin V et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic subjects. J Clin Endocrinol Metab 2004 89 : 638 45.
47. Saveanu A Lavaque E Gunz G Barlier A Kim S Taylor JE et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002 87 : 5545 52.